BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.
Metrics to compare | PHGE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHGEPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.4x | −3.0x | −0.5x | |
PEG Ratio | −0.02 | −0.03 | 0.00 | |
Price/Book | 2.0x | 2.5x | 2.6x | |
Price / LTM Sales | - | 11.1x | 3.2x | |
Upside (Analyst Target) | - | 516.5% | 40.5% | |
Fair Value Upside | Unlock | 4.9% | 4.4% | Unlock |